A cost analysis of switching calcium channel blockers: A one-year post-formulary decision review

P and T

Volumn 27, Issue 7, 2002, Pages 333-337+344

  Smith, Gilda M ^a   Harper Jr , Isiah M ^a   Stowers, Allan D ^a  

^a Pharm Serv at the Columbus Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; FELODIPINE; NIFEDIPINE;

ADULT; AGED; ANGINA PECTORIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG FORMULATION; FEMALE; HEALTH CARE COST; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; REVIEW;

EID: 0036325984     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Blood pressure as a cardiovascular risk factor. Prevention and treatment
2. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNCVI)
3. Antihypertensive drug therapy. The effect of JNC criteria on prescribing patterns and patient status through the first year
4. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data
5. First line drugs in chronic stable effort angina - The case for newer, longer-acting calcium channel blocking agents
6. The safety of calcium-channel blockers
7. Prolonged antihypertensive effect of amlodipine: A prospective double-blind randomized study
8. Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension
9. Pharmacological differences between calcium antagonists
10. Pharmacoeconomic considerations in the management of hypertension
11. Trends in antihypertensive drug use in the United States. Do the JNCV recommendations affect prescribing?
12. Projecting future drug expenditures - 1999
13. Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension
14. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension
15. Clinical outcome of a mandatory formulary switch for dihydropyridine calcium channel blocker therapy at a veteran's administration medical center
16. Conversion from amlodipine to felodipine ER: Did the change fulfill expectations?
17. Dihydropyridine formulary conversion: A review of economics and outcomes
18. Usefulness of amlodipine for angina pectoris
19. Is initial dose titration of amlodipine worthwhile in patients with mild to moderate hypertension?
20. Treatment of mild hypertension study. Final results
21. Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses
22. Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 hour blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: A forced titration study
23. Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients
24. The costs of interrupting antihypertensive drug therapy in a Medicaid population
25. Taking antihypertensive medication-controlling or co-operating with patients?
26. Maintaining long-term control of blood pressure: The role of improved compliance
27. Patient compliance and therapeutic coverage: Amlodipine versus nifedipine (slow-release) in the treatment of angina pectoris
28. Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release
29. Antihypertensive drag therapies and the risk of ischemic stroke